Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foreign Exchange Rates Said To Bode Well For Chinese Pharmas

This article was originally published in PharmAsia News

Executive Summary

Chinese drug makers can expect to benefit by a foreign exchange rate that makes the yuan stronger against the American dollar and other currencies. The situation is expected to lead to greater foreign investments in China's industry and give drug makers greater domestic purchasing power. At the same time, foreign competitors face greater operating costs in China, leading them to expect a greater contribution from alliances with other Chinese firms. The estimates come from Synthetic Organic Chemical Manufacturers Association, a global group for chemical companies. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel